Overview

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

Status:
Completed

Trial end date:
2009-04-01

Target enrollment:

Participant gender:

Summary

To demonstrate the efficacy of 80 mg adalimumab monthly dosing compared with placebo and demonstrate the non-inferiority of monthly dosing of 80 mg adalimumab compared with dosing of 40 mg adalimumab every other week.

Phase:

Phase 3

Details

Lead Sponsor:

Abbott

Treatments:

Adalimumab